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ABSTRACT:
Spores of some species of the strictly anaerobic bacteria Clostridium naturally 
target and partially lyse the hypoxic cores of tumors, which tend to be refractory 
to conventional therapies. The anti-tumor effect can be augmented by engineering 
strains to convert a non-toxic prodrug into a cytotoxic drug specifically at the tumor 
site by expressing a prodrug-converting enzyme (PCE). Safe doses of the favored 
prodrug CB1954 lead to peak concentrations of 6.3 µM in patient sera, but at these 
concentration(s) known nitroreductase (NTR) PCEs for this prodrug show low 
activity. Furthermore, efficacious and safe Clostridium strains that stably express a 
PCE have not been reported. Here we identify a novel nitroreductase from Neisseria 
meningitidis, NmeNTR, which is able to activate CB1954 at clinically-achievable 
serum concentrations. An NmeNTR expression cassette, which does not contain an 
antibiotic resistance marker, was stably localized to the chromosome of Clostridium 
sporogenes using a new integration method, and the strain was disabled for safety 
and containment by making it a uracil auxotroph. The efficacy of Clostridium-Directed 
Enzyme Prodrug Therapy (CDEPT) using this system was demonstrated in a mouse 
xenograft model of human colon carcinoma. Substantial tumor suppression was 
achieved, and several animals were cured. These encouraging data suggest that the 
novel enzyme and strain engineering approach represent a promising platform for 
the clinical development of CDEPT.
INTRODUCTION
Biotechnology potentially offers unconventional 
routes to new cancer therapies, and research in this 
area has focused on using viruses as vectors to deliver 
therapeutic genes to tumors. Unfortunately, issues with the 
safety of viral vectors have been encountered [1, 2] and 
only recently has a virus system showing good specificity 
and tumor infiltration been described [3]. Several types of 
bacteria have also been investigated as delivery vectors, 
and as therapeutics in their own right [4, 5]. Spores of 
some species of Clostridium, which are strictly anaerobic 
bacteria, naturally target tumors with high specificity 
following intravenous administration, because the dormant 
spores can germinate and grow only in the hypoxic/
necrotic cores of solid tumors [6–8] which are difficult 
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to target using viral vectors [9, 10]. The growing bacteria 
secrete proteases inside the tumor, rapidly digesting 
the tumor mass. This approach is especially interesting 
because it directly targets the hypoxic cells in poorly 
vascular regions which are refractory to conventional 
treatments. Any Clostridium cells entering normal tissue 
from a colonized tumor would be poisoned by oxygen and 
die.
Stringent spacial containment by oxygen is an 
excellent safety feature, absent from treatments using 
bacteria that are not strict anaerobes [11, 12], but it also 
allows neoplastic cells at the oxygenated tumor periphery 
to escape proteolysis [13]. Therefore, we and others have 
sought to augment the anti-tumor effect of Clostridium 
strains by genetically modifying them to express 
therapeutic proteins, mainly enzymes which sensitize the 
tumor to specific chemotherapeutic agents [14–20]. The 
prodrug CB1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide) 
shown in Figure 1 is an attractive candidate because its 
clinical safety has been demonstrated [21], and because 
a 10,000-fold increase in toxicity is achieved upon its 
activation by a suitable nitroreductase (NTR) enzyme to 
the 4-hydroxylamine (4HX) derivative 5-(aziridin-1-yl)-
4-hydroxylamino-2-nitrobenzamide. The 4HX derivative 
forms a potent DNA cross-linking agent [22, 23] which, 
importantly, has been shown to kill both proliferating and 
non-proliferating cells [24], both of which are present in 
hypoxic tumor areas.
Encouraging preclinical efficacy data have been 
achieved with genetically engineered NTR-expressing 
Clostridium [19, 20]. However, for this Clostridium-
Directed Enzyme-Prodrug Therapy (CDEPT) using 
CB1954 to be suitable for clinical evaluation, two issues 
must be addressed. Firstly, the poor kinetics of CB1954 
activation by known NTRs must be improved upon. 
The maximum concentration of CB1954 which can be 
safely achieved in patient serum is only 6.3 µM [21], at 
which concentration previously-reported enzymes are not 
saturated. Secondly, a recombinant Clostridium strain must 
be constructed with properties appropriate for clinical 
application. The DNA encoding the prodrug-converting 
enzyme should be stably localized to the chromosome 
rather than carried by a plasmid, antibiotic-resistance 
gene(s) used during strain construction must be removed, 
and preferably the organism should be disabled to prevent 
its growth in the event of a release into the environment. A 
strain meeting these criteria has not been described in any 
report to-date. Here we solve each of these problems and 
demonstrate the efficacy of CDEPT in a mouse xenograft 
model of human colon carcinoma, using CB1954 and a 
recombinant Clostridium strain potentially suitable for 
clinical trial.
RESULTS
A novel NTR which efficiently activates CB1954 at 
clinically-achievable concentrations
Known enzymes with NTR activity against CB1954 
are NAD(P)H-dependent quinone reductases belonging 
to one of two large protein families, Pfam PF00881 
‘Nitroreductase’ and Pfam PF02525 ‘Flavodoxin_2’, 
such as E. coli NfnB [25] and Bacillus amyloliquefaciens 
YwrO [26] respectively. We identified homologs of 
these proteins in the genome sequences of organisms or 
genomic DNA available in our laboratory (see Supporting 
Information), and investigated the activity of several of 
these against CB1954. Each gene encoding a candidate 
CB1954-activating enzyme was cloned in an E. coli 
expression vector. Crude cell lysates were used in initial 
screens for functional expression, and then to test for 
CB1954 nitroreductase activity using an HPLC assay (see 
Supporting Information). CB1954 was rapidly consumed 
by cell lysates containing the NfnB homolog from 
Haemophilus somnus 129PT or Neisseria meningitidis 
MC58. Therefore these two enzymes, which we designate 
HsoNTR and NmeNTR respectively, were studied in more 
detail.
NmeNTR and HsoNTR were each affinity-tagged, 
over-expressed, purified, and the CB1954 nitroreductase 
activities of the purified proteins characterized using 
the HPLC assay. The reaction products and kinetic 
parameters of these enzymes with respect to CB1954 
and NADH were determined (Table 1). Both NmeNTR 
and HsoNTR reduce CB1954 only at the 4-nitro group, 
Figure 1: The prodrug CB1954 is a low-toxicity 
monofunctional DNA-alkylating agent, but can be 
converted to a much more toxic bifunctional DNA-
alkylating agent upon 2 x 2-electron reduction of 
the 4-nitro or 2-nitro group to the corresponding 
hydroxylamine. The 4-hydroxylamine is more cytotoxic than 
the 2-hydroxylamine. Some NAD(P)H-dependent nitroreductase 
(NTR) enzymes can catalyse this reaction, with varying kinetics 
and nitro group specificity (see Table 1).
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producing the highly toxic 4HX derivative. This contrasts 
with the widely-studied E. coli NfnB which reduces 
CB1954 at either the 4-nitro group or 2-nitro group, 
producing equimolar quantities of the 4HX derivative 
and much less toxic 2-hydroxylamine (2HX) derivative 
(5-(aziridin-1-yl)-2-hydroxylamino-4-nitrobenzamide) 
[27, 28]. Moreover, the kinetic parameters of HsoNTR 
and NmeNTR differ dramatically from those of E. coli 
NfnB and other published enzymes (Table 1). Crucially, 
NmeNTR is the first reported enzyme with a Km
CB1954 lower 
than 6.3 µM, the maximum concentration of CB1954 
which can be safely achieved in patient serum. NmeNTR 
would therefore approach saturation with CB1954 in 
a therapeutic regime using the maximum clinically-
recommended dose, so the prodrug would be efficiently 
activated and high levels of tumor-specific cytotoxicity 
achieved.
Construction of NTR-expressing Clostridium 
strains that are stable, disabled, and lack 
antibiotic marker genes
To establish whether the apparently superior 
kinetic properties of NmeNTR would result in improved 
therapeutic performance, we sought to construct and 
compare strains of Clostridium sporogenes NCIMB 10696 
expressing either NmeNTR or the most-studied CB1954-
activating enzyme E. coli NfnB in an in vivo model. C. 
sporogenes NCIMB 10696 is one of the tumor-targeting 
Clostridium strains currently most studied as a potential 
therapeutic agent [16–20] along with Clostridium novyi 
NT [29–32].
In previous CDEPT studies nitroreductases 
have been expressed using autonomous plasmids, but 
these exhibit segregational instability [33], causing the 
proportion of plasmid-containing cells in a population 










Products Source / Comment
NmeNTR 4.04 (NADH)
15.23 (NADPH)
2.47 1.636 (NADH)6.166 (NADPH) 188 4HX
NTR from Neisseria 










0.596 (NADPH) 644 4HX
NTR from Haemophilus 
somnus 129PT (this study).




7.5 170 0.044 5 4HX + 2HX
Mutant obtained by protein 
engineering (Searle et al., 
2004 and Race et al., 2007).
HinNTR 56.2 690 0.081 ND 4HX
NTR from Haemophilus 
influenzae (Theys et al., 
2006). Highest Kcat  value of 
any reported enzyme.
NfsA 2.60 (NADH)20.9 (NADPH)
18 (NADH)
140 (NADPH) 0.15 ND 2HX
A second E. coli NTR (Vass 
et al., 2009).
BliNTR 6.4 30 0.213 820 4HX




F124W 26.6 259 0.103 ND 4HX
Mutant of FRase I from 
Vibrio fischeri obtained by 
protein engineering (Swe 
et al., 2012).
The enzymes shown include those with the most favourable values reported for Kcat, Km
CB1954, and Kcat /Km
CB1954.
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to decrease during growth. Therefore expression of a 
plasmid-borne NTR is likely to be poor and heterogenous 
in a tumor colonized through many generations of bacterial 
growth [34] following the initial infiltration of a small 
number of plasmid-containing spores. Plasmids also carry 
a risk of transfer to other organisms. To overcome these 
issues, we opted to use expression constructs localized 
to the chromosome, which has complete segregational 
stability and no mechanism for transfer. The insertion of 
heterologous expression constructs into the chromosome 
of tumor-targeting Clostridium sp. has not previously 
been reported, but is now possible using methods for 
chromosomal integration in C. sporogenes that we have 
recently developed [35–37].
An expression cassette was constructed using a 
strong, constitutive promoter derived from the ferredoxin 
gene fdx of C. sporogenes to direct expression of 
NmeNTR from a synthetic coding sequence sequence with 
codon usage optimized to suit C. sporogenes. A similar 
expression cassette for E. coli NfnB was also constructed. 
The NmeNTR expression cassette was initially inserted 
into the C. sporogenes chromosome using the ClosTron 
method [35, 36] which employs a modified bacterial 
Group II intron (a type of mobile retro-element [38]) to 
deliver the sequence of interest. Recombinant clones were 
isolated using the antibiotic erythromycin, resistance to 
which is conferred by the marker gene ermB within 
the insertion. As antibiotic resistance is undesirable in 
therapeutic strains, subsequent removal of ermB from the 
chromosome using FLP recombinase was attempted, but 
was unsuccessful (see Supporting Information).
To circumvent the need for marker removal, we used 
our recently-developed integration method ACE, in which 
an antibiotic selection marker need not be incorporated 
into the chromosome along with the expression cassette 
[37]. NmeNTR and E. coli NfnB expression cassettes 
were inserted into the C. sporogenes chromosome using 
integration vector pMTL-JH27, which targets pyrE, a 
gene involved in pyrimidine biosynthesis. By inactivating 
pyrE during integration, recombinant cells are also uracil 
auxotrophs and effectively disabled from growth in the 
environment. The concept of disabling a strain to ensure 
containment was proposed at the advent of recombinant 
DNA technology [39] and has recently been applied to 
restrict Salmonella amino acid auxotrophs to tumors [11, 
12]. Using this approach, the desired recombinant C. 
sporogenes strains containing E. coli NfnB and NmeNTR 
were readily obtained, and were designated E1 and N1, 
respectively (Figure 2A and B). The ‘empty’ vector pMTL-
JH27 was previously used to generate a pyrE mutant 
without an expression cassette [37] which we used as a 
control in this study (Figure 2A).
Strain characterization in vitro
To determine whether the heterologous 
nitroreductases were functionally expressed by strains E1 
and N1, we measured the menadione reductase activity 
in cell lysates of these strains and compared them to the 
wild type and the pyrE mutant. Cells lysates of both E1 
and N1 contained menadione reductase activity elevated 
significantly above the endogenous levels measured in the 
controls (Figure 2C).
The disablement of E1, N1 and the pyrE mutant 
was confirmed by sub-culturing cells of these strains 
and the wild type from the complex medium TYG onto 
Figure 2: Construction and in vitro characterization 
of C. sporogenes therapeutic strains. (A) Chromosomal pyrE 
locus of therapeutic strains and control strains. WT, wild 
type; ΔpyrE, a mutant constructed previously by integrating 
the ‘empty’ cloning site (lacZ’) of pMTL-JH27 [37]; N1, the 
strain containing a NmeNTR expression cassette; E1, the strain 
containing an E. coli NfnB expression cassette; angled arrows, 
fdx promoter. (B) Successful integration shown by PCR using 
chromosome-specific primer Csp-pyrD-sF2 in combination with 
insert-specific primer M13F. MW, 2-Log DNA Ladder (NEB) 
molecular weight marker; plasmid, pMTL-JH27 derivative 
containing NmeNTR or NfnB cassette accordingly; WT, wild-
type C. sporogenes genomic DNA; N1 and E1, genomic DNA 
from strain N1 or E1 respectively. (C) Functional expression of 
NmeNTR and NfnB, in strains N1 and E1 respectively, indicated 
by specific menadione reductase activities in cell lysates. Data 
shown are the mean of three independent experiments, error bars 
show standard deviation. N1 and E1 show specific menadione 
reductase activities elevated above the background activity of 
endogenous quinone reductases seen in WT and ΔpyrE. (D) 
NTR-expressing and control strains are equally able to form 
spores. Strains were grown in complex medium (TYG) for 
five days, heated to inactivate vegetative cells, and spore titres 
were determined by plating. A non-sporulating Δspo0A mutant 
constructed previously [35] is included as a control. Data shown 
are the mean of three independent experiments, error bars show 
standard deviation.
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plates of a defined growth medium either with or without 
supplementary uracil. The wild type grew equally well 
with or without the uracil supplement, whereas E1, N1 and 
the pyrE mutant were unable to grow without exogenous 
uracil, confirming their disablement, a uracil auxotrophic 
phenotype.
CDEPT depends upon the ability of Clostridium to 
form spores, the metabolically-dormant, highly-robust 
form suitable for intravenous administration and for long 
periods of storage. Therefore it was necessary to determine 
whether the ability of the recombinant strains to form 
spores had been affected by the inactivation of pyrE, the 
addition of the NTR expression cassettes, or the sub-
culturing steps during the genetic modification procedure. 
The wild type, E1, N1 and the pyrE mutant were cultivated 
in TYG broth, in which the wild type forms spores over 
time. A spo0A mutant, which is completely unable to form 
spores, was also included as a control [35]. Samples taken 
over several days were heated to inactivate vegetative 
cells, and the titre of heat-resistant colony-forming units 
(corresponding to viable spores) was determined by 
dilution plating (Figure 2D). The spo0A mutant formed 
no colonies following heat treatment, confirming that the 
procedure inactivated all vegetative cells. E1, N1 and the 
pyrE mutant were all able to form spores, and did so at 
the same rate as the wild type, and to the same final titer.
CDEPT treatment of tumors in vivo
Since strains E1 and N1 express stably-integrated 
NTR under the regulatory control of a strong promoter 
without inclusion of any antibiotic resistance gene, 
we next determined whether administration of these 
clinically-applicable strains in combination with prodrug 
administration to tumor-bearing animals would result in 
anti-tumor efficacy. To do so, we compared the effect 
in animals that received (1) no treatment, (2) CB1954 
prodrug alone, (3) sham treatment (spores and vehicle), 
(4) pyrE mutant control spores in combination with 
CB1954 and (5) N1 or E1 spores in combination with 
CB1954, each in a standard experimental tumor growth 
delay setting. This choice of groups allowed us to compare 
the contribution of the two major improvements reported 
here, stable integration and improved enzyme kinetics. 
Spores were collected, quantified and intravenously 
administered at a concentration of 5x107 cfu per animal 
when tumors reached a volume of ~250 mm3, followed 
five days later by sham or prodrug administration. 
Colonization evaluation in randomly chosen tumors from 
each group (n≥14 per group) showed equal numbers of the 
C. sporogenes cells per g tumor tissues for all strains, with 
>99% of cfu being in the metabolically active vegetative 
form. Colonization was also confirmed by gram staining. 
In tumors, C. sporogenes vegetative cells are visible as 
purple, gram-positive rods (Figure 3C). Disablement of 
the strain by knocking out pyrE thus did not affect the 
excellent tumor-colonizing capacity of C. sporogenes. In 
line with our previous observations [19] administration 
of prodrug alone did not result in any effect, and only a 
small (non-significant) growth delay was observed upon 
administration of spores alone (sham) or control spores 
in combination with CB1954 (Figure 3 A). Strikingly, 
combining spores of strain E1 or N1 with CB1954 
Figure 3: The NTR-expressing therapeutic strains are efficacious in CB1954 therapy in vivo. (A) Growth curves of HCT116 
tumors treated as indicated in the legend. Spores (5 x 107) were injected on day 0 when tumors reached a volume of ~250 mm3 and CB1954 
prodrug (15 mg/kg) or sham treatment was given for 5 consecutive days starting at day 5 post spore injection. Data shown are average ± 
SEM. (B) Growth delay of individual tumors in the different groups. Growth delay is defined as the time for the tumor to reach three times 
its volume at the start of the prodrug or sham treatment. Statistical differences between groups are calculated using the non-parametric 
Mann-Whitney test (*, p<0.05; **, p<0.01; *, p<0.001) (C) Representative gram staining of tumor sections showing colonization of the 
tumor by C. sporogenes vegetative cells following spore administration, germination in the tumor, and outgrowth. C. sporogenes vegetative 
cells are visible as gram-positive purple rods and reside in the necrotic area of the tumor. HCT116 nuclei (pink) are counterstained with 
iodine solution.
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resulted in a significant growth delay, the effect being most 
pronounced for N1 (p<0.001, Figure 3 B). This suggests 
that the superior kinetic properties of NmeNTR, which 
allow conversion of the prodrug to its toxic derivative at 
a much lower concentration than E. coli NfnB, contribute 
substantially to the observed effect. The most striking 
effect we observed was the disappearance of several 
tumors in both CDEPT groups. In the E1/CB1954 group, 
two out of 16 tumors completely disappeared and in the 
N1/CB1954 four out of 16 tumors completely disappeared 
(Figure S1). During the treatment, a mild and transient 
weight loss could be observed and the animals recovered 
completely during further follow-up time.
DISCUSSION
The poor activity of known nitroreductases at 
clinically-relevant CB1954 concentrations has led to 
several previous attempts to obtain an enzyme with more 
suitable kinetic properties, by screening native enzymes 
[26, 40–43] and/or protein engineering [43–47] with some 
success. However, NmeNTR, the N. meningitidis homolog 
of E. coli nitroreductase NfnB reported here, is the first 
example of an enzyme with a Km
CB1954 value that can be 
exceeded by the clinically-achievable serum concentration 
of the prodrug. This Km
CB1954 value (2.47 µM) is also seven-
fold lower than the lowest previously reported (NfsA, 18 
µM, Table 1). This key improvement makes NmeNTR 
much more suitable for clinical application than other 
known enzymes.
NmeNTR reduces only the 4-nitro group of 
CB1954, producing the highly-cytotoxic 4HX derivative, 
unlike E. coli NfnB which produces both the 4HX and 
2HX derivatives in similar proportions [27, 28]. Among 
the enzymes whose CB1954 nitroreductase activity has 
now been characterized, specificity for the 4-nitro group 
appears to be typical (Table 1). E. coli NfnB, although the 
most widely studied CB1954 nitroreductase, is unusual in 
this respect. The 4HX derivative is far more cytotoxic than 
the 2HX derivative [22] which suggests that an enzyme 
such as NmeNTR with specificity for the 4-nitro group 
would lead to greater tumor-specific cytotoxicity.
By localizing expression cassettes to the 
chromosome using double crossover homologous 
recombination, we have constructed stable strains that 
lack both antibiotic resistance markers and any mechanism 
for transfer of the heterologous sequence. This feature 
represents a major improvement over previous studies 
in terms of efficacy and safety, as the instability of 
known plasmid replicons in C. sporogenes has been 
established [33] and transfer of natural and recombinant 
conjugal plasmids and transposons is known to occur in 
C. sporogenes and close relatives.
C. sporogenes is naturally confined to the hypoxic 
tumor core by oxygen, and the disabling pyrE mutation we 
introduce would serve to severely limit growth of modified 
strains in the environment in the event of accidental 
release from a clinical setting. Tumor containment and/
or targeting features have been described for other 
recombinant bacterial strains with anti-tumor potential, 
such as Salmonella [11, 12]. The use of elegant synthetic 
regulatory mechanisms has also been proposed for 
containment [4] but we are cautious of their use for this 
purpose, and suggest that physiological mechanisms may 
be more appropriate. Any system in which containment 
depends upon the continued function of introduced 
component(s) will be vulnerable to failure through 
spontaneous loss-of-function mutations. Such mutations 
are inevitable at some frequency, and mutants would have 
a selective advantage for growth outside the tumor, so 
these systems would be inherently fragile. In contrast, no 
loss-of-function mutation is likely to allow an auxotrophic 
mutant of a strict anaerobe, as reported here, to escape the 
tumor environment.
Our approach to constructing stable, disabled, 
antibiotic marker-free strains of Clostridium expressing 
heterologous genes represents a platform for future efforts 
to build upon, as it provides a tumor-specific delivery 
system for the development of safe and effective gene 
therapies. The novel PCE NmeNTR in combination with 
CB1954 is a promising candidate. Besides cytotoxicity, 
strains could be engineered to have additional clinically-
useful properties. For example, we are currently working 
to enable imaging of tumors undergoing Clostridium 
therapy via clinically-relevant imaging modalities such as 
PET. With the key strain engineering challenges overcome, 
a clinical trial to realize this therapy is now in prospect.
METHODS
Full methods are given in SI Appendix, Methods.
Enzyme characterization
Genes encoding homologs of nfnB and ywrO were 
PCR-amplified from genomic DNA or cell lysates. E. 
coli expression plasmids for each gene were constructed 
by standard methods. Menadione reductase activities 
of lysates of E. coli cells containing the expression 
plasmids were determined using a spectrophotometric 
assay, and CB1954 nitroreductase activities of lysates 
were determined using an HPLC assay. Specific activities 
were calculated using protein concentrations of lysates 
determined using the Bradford assay. The 4HX and 2HX 
derivatives of CB1954 were identified with reference 
to standards, their known absorbance spectra, and their 
anticipated column retention times. For determination of 
kinetic parameters using the same CB1954 nitroreductase 
assay, NTR expression plasmids were modified to encode 
C-terminal 6xHis tags, and enzymes were purified using a 
Novagen His-Bind kit.
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Construction of recombinant C. sporogenes
C. sporogenes was cultured anaerobically. Plasmids 
were transferred to C. sporogenes by conjugation from 
an E. coli donor as described previously [33]. Expression 
cassettes for NmeNTR and E. coli NfnB were constructed 
using derivatives of the fdx promoter from C. sporogenes 
and a synthetic, codon-optimized gene (Entelechon 
GmbH). Expression cassettes were initially inserted 
into the C. sporogenes chromosome using the pyrF-
specific Group II intron plasmid pMTL007C-E2::Csp-
pyrF-595s, and FLP-mediated removal of the ermB 
attempted as described previously [36]. Subsequently, 
expression cassettes were inserted into the C. sporogenes 
chromosome using the pyrE integration plasmid pMTL-
JH27 as described previously [37].
Characterization of recombinant C. sporogenes
Menadione reductase activities of lysates of C. 
sporogenes cells were determined to establish functional 
expression of the heterologous NTRs. Uracil auxotrophy 
/ prototrophy was determined by sub-culturing fresh C. 
sporogenes colonies grown on the complex medium 
TYG onto plates of the defined growth medium MI either 
with or without supplementary uracil. Spores titres were 
determined as colony-forming units resistant to heat-
treatment at 80 °C for 20 minutes.
Mouse xenograft tumor model
Human colorectal HCT116 carcinoma cells were 
injected subcutaneously into adult NMRI nu/nu mice. 
Tumor volumes were determined three times per week 
using calipers. 5x107 spores were administered when 
tumors reached a volume of ~250 mm3, and sham or 
prodrug treatment was started five days later. CB1954 
was administered intraperitoneally at a concentration of 
15 mg/kg for five consecutive days. At the end of the 
follow-up period, colonization levels were determined in 
tumors and normal tissues as described previously [48]. 
Tumor growth delay was determined as the time from the 
start of the treatment necessary for a tumor to triple in 
volume. Statistical significance was tested using a non-
parametric Mann Whitney test. All animal testing was 
performed in accordance with local institutional guidelines 
and approved by the Animal Ethics Committee.
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